Details of the Drug Combination

General Information of Drug Combination (ID: DCDJF22)

Drug Combination Name
Cisatracurium Magnesium Sulfate
Indication
Disease Entry Status REF
Muscle Relaxation Phase 2 [1]
Component Drugs Cisatracurium   DMUZPJ5 Magnesium Sulfate   DMVEK07
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Cisatracurium
Disease Entry ICD 11 Status REF
Muscle spasm MB47.3 Approved [2]
Cisatracurium Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Cholinergic receptor unspecific (CHR) TTUPDWN NOUNIPROTAC Antagonist [5]
Neuronal acetylcholine receptor alpha-2 (CHRNA2) TTF4E0J ACHA2_HUMAN Antagonist [6]
------------------------------------------------------------------------------------
Indication(s) of Magnesium Sulfate
Disease Entry ICD 11 Status REF
Acute pain MG31 Approved [3]
Familial primary hypomagnesemia N.A. Approved [4]
Hypertension, pregnancy-induced N.A. Approved [4]
Mild pre-eclampsia N.A. Approved [4]
Non-arteritic anterior ischemic optic neuropathy 9C40.40 Approved [4]
Pain MG30-MG3Z Approved [4]
Severe pre-eclampsia N.A. Approved [4]
Traumatic brain injury NA07.Z Approved [4]
Magnesium Sulfate Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
N-methyl-D-aspartate receptor (NMDAR) TT9IK2Z NOUNIPROTAC Antagonist [7]
------------------------------------------------------------------------------------
Magnesium Sulfate Interacts with 4 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Kallikrein-8 (KLK8) OTGVGHXY KLK8_HUMAN Increases Activity [8]
Renin (REN) OT52GZR2 RENI_HUMAN Increases Activity [9]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Decreases Expression [10]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [10]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Neuromuscular Block DCFSCKA N. A. Phase 4 [11]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT05736744) Effect of Magnesium Sulphate Pretreatment in Pediatric Laparoscopy
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42.
4 Magnesium Sulfate FDA Label
5 Bradycardia produced by pyridostigmine and physostigmine. Can J Anaesth. 1997 Dec;44(12):1286-92.
6 Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
7 Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95.
8 Activation and enzymatic characterization of recombinant human kallikrein 8. Biol Chem. 2006 Jun;387(6):723-31. doi: 10.1515/BC.2006.091.
9 Haemodynamic and endocrine effects of deliberate hypotension with magnesium sulphate for cerebral-aneurysm surgery. Eur J Anaesthesiol. 1991 Mar;8(2):115-21.
10 Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
11 ClinicalTrials.gov (NCT02483611) Effects of Intravenous Lidocaine Associated With Magnesium Sulfate on the Cisatracurium-Induced Neuromuscular Block